Author: Bundred, Nigel J

Source: Women's Health, Volume 2, Number 5, September 2006 , pp. 673-685(13)

Publisher: Future Medicine

Abstract:

Letrozole, an aromatase inhibitor, demonstrates consistent superiority over tamoxifen in various treatment settings, has the only significant survival advantage according to results from a Phase III randomized trial, and is the only aromatase inhibitor approved as an extended adjuvant therapy in the treatment of breast cancer. Initial adjuvant letrozole significantly prolongs disease-free survival, especially reducing the risk of distant metastasis, and offers a significant disease-free survival benefit to patients at an increased risk of relapse (node-positive and chemotherapy-treated patients) when compared with tamoxifen. These findings led to its recommendation as an initial adjuvant therapy in the latest St Gallen guidelines. Similar findings were reported when letrozole was administered after completion of 5 years of adjuvant tamoxifen. The benefit of letrozole also increases with the duration of treatment. Overcoming the development of resistance to endocrine therapy is under investigation. As a potent aromatase inhibitor, letrozole is the ideal drug for tailored combination treatment regimens of the future.

Keywords: adjuvant therapy; aromatase inhibitor; breast cancer; combination therapy; estrogen; letrozole; postmenopausal women; recurrence risk; tamoxifen

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.2217/17455057.2.5.673

Affiliations: 1: South Manchester University Hospital, Education & Research Centre, Southmoor Road, Manchester, M23 9LT, UK., Email: nigel.J.bundred@manchester.ac.uk

Publication date: 2006-09-01

More about this publication?

• Women's Healthprovides a forum for specialists addressing those conditions that are unique to women or far more prevalent in women than in men. The journal focuses on current and emerging topics relating to the safe and effective management of therapy in women, taking into account issues such as key areas such as women's physiology and life-cycle hormonal changes, with all articles subject to rigorous peer review.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• E-Access Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine ,  Public Health ,  Gender Studies
• By this author: Bundred, Nigel J

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers